Tag: Opdivo

April 5, 2022 Off

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

By Author

The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.

September 28, 2019 Off

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

By BusinessWire

Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.